The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12625000670471
Ethics application status
Approved
Date submitted
12/02/2025
Date registered
25/06/2025
Date last updated
25/06/2025
Date data sharing statement initially provided
25/06/2025
Type of registration
Prospectively registered

Titles & IDs
Public title
Improving Care for possible Traumatic Brain Injury using a Point-Of-Care blood test (ICare-TBI POC) : Verification of the Abbott i-STAT TBI test
Scientific title
Improving Care for possible Traumatic Brain Injury by verification of the precision of the i-STAT TBI Point-Of-Care blood test for the biomarkers Neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP).
Secondary ID [1] 313948 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Traumatic Brain Injury 336655 0
Condition category
Condition code
Emergency medicine 333150 333150 0 0
Other emergency care
Neurological 333151 333151 0 0
Other neurological disorders
Injuries and Accidents 333152 333152 0 0
Other injuries and accidents

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
During an emergency department (ED) visit patients identified as having mild Traumatic Brain Injury (mTBI) and whom the attending physician has ordered a computerised tomography (CT) head scan will be consented to allow data collection and a single blood draw. They will then have blood drawn. The i-STAT TBI POC test will measure the concentrations of two biomarkers, UCH-L1 and GFAP. The test will not be used in clinical practice, the results will not be known to attending physicians. Participation ends after discharge from ED.
Intervention code [1] 330540 0
Diagnosis / Prognosis
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 340721 0
Precision of measurements for glial fibrillary acidic protein (GFAP)
Timepoint [1] 340721 0
Following collection of all blood samples.
Primary outcome [2] 340722 0
Proportion of patients with biomarker concentrations above the manufacturer recommended thresholds
Timepoint [2] 340722 0
Following collection of all blood samples.
Primary outcome [3] 341738 0
Precision of measurements for ubiquitin C-terminal hydrolase-L1 (UCH-L1)
Timepoint [3] 341738 0
Following collection of all blood samples.
Secondary outcome [1] 444858 0
Haemolysis interference
Timepoint [1] 444858 0
Following ED blood draw
Secondary outcome [2] 444859 0
Rates of any finding on the CT scan
Timepoint [2] 444859 0
Following a CT head on the day of ED presentation
Secondary outcome [3] 444860 0
Rates of representation to the ED with symptoms relating to the mTBI
Timepoint [3] 444860 0
30 days post ED presentation
Secondary outcome [4] 444861 0
Rate of death (all cause)
Timepoint [4] 444861 0
30 days post ED presentation

Eligibility
Key inclusion criteria
• Adults>= 18 years of age.
• Presenting within 24 hours of suspected mild or moderate TBI.
• Attending physician’s initial judgment is the need for a head CT.
• Glasgow Coma Score (GCS) on arrival in the ED 13-15
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• Patients presenting >24 hours of suspected injury or with an unknown time of onset predicted to be >24 hours
• GCS <13
• Pre-existing brain injury at time of presentation, such as recent TBI or recent stroke
• Pre-existing neurological condition such as dementia, acute psychosis, motor neurone disease, multiple-sclerosis, learning difficulties
• Unable for them or their guardian to give verbal consent
• Clinician perceived need to do an immediate CT irrespective of biomarker results because of red flags.

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 26884 0
New Zealand
State/province [1] 26884 0
Canterbury

Funding & Sponsors
Funding source category [1] 318442 0
Commercial sector/Industry
Name [1] 318442 0
Abbott Point of Care
Country [1] 318442 0
United States of America
Primary sponsor type
Charities/Societies/Foundations
Name
Emergency Care Foundation
Address
Country
New Zealand
Secondary sponsor category [1] 320838 0
Hospital
Name [1] 320838 0
Christchurch Hospital
Address [1] 320838 0
Country [1] 320838 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 317060 0
Southern Health and Disability Ethics Committee
Ethics committee address [1] 317060 0
Ethics committee country [1] 317060 0
New Zealand
Date submitted for ethics approval [1] 317060 0
14/11/2024
Approval date [1] 317060 0
02/05/2025
Ethics approval number [1] 317060 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 139866 0
Prof Martin Than
Address 139866 0
Canterbury District Health Board and Emergency Care Foundation 21 Taylors Mistake Road Sumner Christchurch 8081
Country 139866 0
New Zealand
Phone 139866 0
+64 3 326 7599
Fax 139866 0
Email 139866 0
Contact person for public queries
Name 139867 0
Martin Than
Address 139867 0
Canterbury District Health Board and Emergency Care Foundation 21 Taylors Mistake Road Sumner Christchurch 8081
Country 139867 0
New Zealand
Phone 139867 0
+64 3 326 7599
Fax 139867 0
Email 139867 0
Contact person for scientific queries
Name 139868 0
Professor John Pickering
Address 139868 0
c/- Emergency Care Foundation P O Box 13-149 Christchurch 8140
Country 139868 0
New Zealand
Phone 139868 0
+64 21 2537877
Fax 139868 0
Email 139868 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Not for public consumption. These patients are all undergoing clinical assessment and it is not appropriate to make their details public even after de-identification because it may be possible to re-identify the patients.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.